Home › Companies › RIGEL PHARMACEUTICALS INC. › 2023-2024

RIGEL PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and RIGEL PHARMACEUTICALS INC.’s Form 8-K, filed May 29, 2024 (Item 5.07 on EDGAR). Page generated November 1, 2026.

7Reported items
127Asset managers
1,012Fund votes
May 24, 2024Meeting date

Results at a glance

Meeting of May 24, 2024: 4 items on RIGEL PHARMACEUTICALS INC.’s Form 8-K, filed May 29, 2024: 2 elected · 2 approved.

Material dissent

Elect Director: Brian L. Kotzin 76% of votes cast Elected Director under 80%
Elect Director: Gregg A. Lapointe 77% of votes cast Elected Director under 80%
Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan. 52.4% of votes cast Approved Under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore RIGEL PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by RIGEL PHARMACEUTICALS INC.

These tallies are RIGEL PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 29, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

RIGEL PHARMACEUTICALS INC. — official shareholder meeting results, meeting held May 24, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Brian L. Kotzin	78,451,723	--	1,529,351	24,372,506	26,314,869	76%	Elected	—
Elect Director: Gregg A. Lapointe	79,150,066	--	1,525,575	23,677,939	26,314,869	77%	Elected	—
Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan.	53,147,924	48,240,156	2,965,500	--	26,314,869	52.4%	Approved	—
Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.	74,738,206	26,220,078	3,395,296	--	26,314,869	74%	Approved	—

Source: RIGEL PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 29, 2024 — read the filing on EDGAR.

How asset managers voted at the RIGEL PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 127 asset managers that disclosed a RIGEL PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of RIGEL PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Brian L. Kotzin

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD

FOR: 78,451,723WITHHELD: 24,372,506

Details: description as filed, official tally, votes by 44 asset managers

Description as filed by funds: Election of Directors: Brian L. Kotzin

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Brian L. Kotzin”): 78,451,723 for, 24,372,506 withheld, per its Form 8-K filed May 29, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the two nominees for director, to serve until the Company's 2027 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows:”
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 29,062,828 for, 341,735 against, 88,669 abstained.

FOR

FOR: 29,062,828AGAINST: 341,735ABSTAIN: 88,669

Largest asset managers voting on “Election of Directors: Brian L. Kotzin” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	9,061,718	0	0	For
BlackRock	6,943,627	0	0	For
Fidelity	3,795,417	0	0	For
TIAA	2,854,841	0	0	For
Delaware/Macquarie	1,600,000	0	0	For
Voya	1,305,129	0	0	For
Charles Schwab	743,615	0	0	For
Equitable	295,130	314,730	0	Mixed
BRIDGEWAY FUNDS INC	521,200	0	0	For
SEI	475,477	0	0	For
QUANTITATIVE MASTER SERIES LLC	305,297	0	0	For
Lincoln Financial	147,363	0	0	For
Brighthouse	56,766	0	88,669	Mixed
Northern Trust	75,696	0	0	For
Nationwide	74,467	0	0	For
T. Rowe Price	74,332	0	0	For
John Hancock	67,421	0	0	For
Legg Mason	66,563	0	0	For
Goldman Sachs	60,610	0	0	For
Pacific Life	57,810	0	0	For
Russell Investments	51,654	0	0	For
AIG/SunAmerica	45,437	0	0	For
Principal Exchange-Traded Funds	39,688	0	0	For
Bridge Builder Trust	35,340	0	0	For
PFM Multi-Manager Series Trust	34,403	0	0	For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

2. Elect Director: Gregg A. Lapointe

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD

FOR: 79,150,066WITHHELD: 23,677,939

Details: description as filed, official tally, votes by 44 asset managers

Description as filed by funds: Election of Directors: Gregg A. Lapointe

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gregg A. Lapointe”): 79,150,066 for, 23,677,939 withheld, per its Form 8-K filed May 29, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the two nominees for director, to serve until the Company's 2027 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows:”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 29,075,023 for, 329,540 against, 88,669 abstained.

FOR

FOR: 29,075,023AGAINST: 329,540ABSTAIN: 88,669

Largest asset managers voting on “Election of Directors: Gregg A. Lapointe” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	9,061,718	0	0	For
BlackRock	6,943,627	0	0	For
Fidelity	3,795,417	0	0	For
TIAA	2,854,841	0	0	For
Delaware/Macquarie	1,600,000	0	0	For
Voya	1,305,129	0	0	For
Charles Schwab	743,615	0	0	For
Equitable	295,130	314,730	0	Mixed
BRIDGEWAY FUNDS INC	521,200	0	0	For
SEI	475,477	0	0	For
QUANTITATIVE MASTER SERIES LLC	305,297	0	0	For
Lincoln Financial	147,363	0	0	For
Brighthouse	56,766	0	88,669	Mixed
Northern Trust	75,696	0	0	For
Nationwide	74,467	0	0	For
T. Rowe Price	74,332	0	0	For
John Hancock	67,421	0	0	For
Legg Mason	66,563	0	0	For
Goldman Sachs	60,610	0	0	For
Pacific Life	57,810	0	0	For
Russell Investments	51,654	0	0	For
AIG/SunAmerica	45,437	0	0	For
Principal Exchange-Traded Funds	39,688	0	0	For
Bridge Builder Trust	35,340	0	0	For
PFM Multi-Manager Series Trust	34,403	0	0	For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

3. TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK…

No official matchCAPITAL STRUCTURE

Combines 3 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR

Details: description as filed, votes by 44 asset managers

Description as filed by funds: TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF COMMON STOCK (WITHOUT REDUCING THE AUTHORIZED NUMBER OF SHARES OF COMMON STOCK), IF AND WHEN DETERMINED BY THE COMPANY'S BOARD OF DIRECTORS.

The 44 asset managers below reported 29,404,563 for, 88,669 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 29,404,563ABSTAIN: 88,669

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	9,061,718	0	For
BlackRock	6,943,627	0	For
Fidelity	3,795,417	0	For
TIAA	2,854,841	0	For
Delaware/Macquarie	1,600,000	0	For
Voya	1,305,129	0	For
Charles Schwab	743,615	0	For
Equitable	609,860	0	For
BRIDGEWAY FUNDS INC	521,200	0	For
SEI	475,477	0	For
QUANTITATIVE MASTER SERIES LLC	305,297	0	For
Lincoln Financial	147,363	0	For
Brighthouse	56,766	88,669	Mixed
Northern Trust	75,696	0	For
Nationwide	74,467	0	For
T. Rowe Price	74,332	0	For
John Hancock	67,421	0	For
Legg Mason	66,563	0	For
Goldman Sachs	60,610	0	For
Pacific Life	57,810	0	For
Russell Investments	51,654	0	For
AIG/SunAmerica	45,437	0	For
Principal Exchange-Traded Funds	39,688	0	For
Bridge Builder Trust	35,340	0	For
PFM Multi-Manager Series Trust	34,403	0	For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

4. TO APPROVE THE ADJOURNMENT OF THE ANNUAL MEETING TO A LATER DATE OR DATES, IF NECESSARY, TO PERMIT FURTHER SOLICITATION…

No official matchCORPORATE GOVERNANCE

Combines 2 wordings of this item as funds reported it.

99.0% of fund votes cast · no official result

FOR

Details: description as filed, votes by 44 asset managers

Description as filed by funds: TO APPROVE THE ADJOURNMENT OF THE ANNUAL MEETING TO A LATER DATE OR DATES, IF NECESSARY, TO PERMIT FURTHER SOLICITATION AND VOTE OF PROXIES IN THE EVENT THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF THE AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT.

The 44 asset managers below reported 29,133,784 for, 270,779 against, 88,669 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 29,133,784AGAINST: 270,779ABSTAIN: 88,669

Largest asset managers voting on “TO APPROVE THE ADJOURNMENT OF THE ANNUAL MEETING TO A LATER DATE OR DATES, IF NECESSARY, TO PERMIT FURTHER SOL” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	9,061,718	0	0	For
BlackRock	6,943,627	0	0	For
Fidelity	3,795,417	0	0	For
TIAA	2,854,841	0	0	For
Delaware/Macquarie	1,600,000	0	0	For
Voya	1,305,129	0	0	For
Charles Schwab	743,615	0	0	For
Equitable	609,860	0	0	For
BRIDGEWAY FUNDS INC	521,200	0	0	For
SEI	475,477	0	0	For
QUANTITATIVE MASTER SERIES LLC	305,297	0	0	For
Lincoln Financial	0	147,363	0	Against
Brighthouse	56,766	0	88,669	Mixed
Northern Trust	75,696	0	0	For
Nationwide	74,467	0	0	For
T. Rowe Price	0	74,332	0	Against
John Hancock	67,421	0	0	For
Legg Mason	66,563	0	0	For
Goldman Sachs	60,610	0	0	For
Pacific Life	57,810	0	0	For
Russell Investments	51,654	0	0	For
AIG/SunAmerica	45,437	0	0	For
Principal Exchange-Traded Funds	39,688	0	0	For
Bridge Builder Trust	35,340	0	0	For
PFM Multi-Manager Series Trust	34,403	0	0	For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

5. Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan.

Official resultCOMPENSATIONReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

52.4% Approved · of votes cast

FOR 52.4%AGAINST

FOR: 53,147,924AGAINST: 48,240,156

Details: description as filed, official tally, votes by 44 asset managers

Description as filed by funds: To approve an amendment to our 2018 Equity Incentive Plan, as amended (the "Amended 2018 Plan"), to add an additional 6,500,000 shares to the number of shares of common stock authorized for issuance under the Amended 2018 Plan.

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan.”): 53,147,924 for, 48,240,156 against — passed, per its Form 8-K filed May 29, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan.”
Support: 52.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 24,524,201 for, 4,880,362 against, 88,669 abstained.

FORAGAINST

FOR: 24,524,201AGAINST: 4,880,362ABSTAIN: 88,669

Largest asset managers voting on “To approve an amendment to our 2018 Equity Incentive Plan, as amended (the "Amended 2018 Plan"), to add an add” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	9,061,718	0	0	For
BlackRock	6,943,627	0	0	For
Fidelity	3,605,770	189,647	0	For
TIAA	2,854,841	0	0	For
Delaware/Macquarie	0	1,600,000	0	Against
Voya	0	1,305,129	0	Against
Charles Schwab	743,615	0	0	For
Equitable	295,130	314,730	0	Mixed
BRIDGEWAY FUNDS INC	0	521,200	0	Against
SEI	475,477	0	0	For
QUANTITATIVE MASTER SERIES LLC	305,297	0	0	For
Lincoln Financial	0	147,363	0	Against
Brighthouse	0	56,766	88,669	Mixed
Northern Trust	0	75,696	0	Against
Nationwide	0	74,467	0	Against
T. Rowe Price	0	74,332	0	Against
John Hancock	0	67,421	0	Against
Legg Mason	0	66,563	0	Against
Goldman Sachs	0	60,610	0	Against
Pacific Life	57,810	0	0	For
Russell Investments	51,654	0	0	For
AIG/SunAmerica	0	45,437	0	Against
Principal Exchange-Traded Funds	0	39,688	0	Against
Bridge Builder Trust	35,340	0	0	For
PFM Multi-Manager Series Trust	0	34,403	0	Against

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

6. Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive…

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

74% Approved · of votes cast

FOR 74%AGAINST

FOR: 74,738,206AGAINST: 26,220,078

Details: description as filed, official tally, votes by 127 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”): 74,738,206 for, 26,220,078 against — passed, per its Form 8-K filed May 29, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 44 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	9,061,718	0	For
BlackRock	6,943,627	0	For
Fidelity	3,795,417	0	For
TIAA	2,854,841	0	For
Delaware/Macquarie	1,600,000	0	For
Voya	1,305,129	0	For
Charles Schwab	743,615	0	For
Equitable	609,860	0	For
BRIDGEWAY FUNDS INC	521,200	0	For
SEI	475,477	0	For
QUANTITATIVE MASTER SERIES LLC	305,297	0	For
Lincoln Financial	147,363	0	For
Brighthouse	56,766	88,669	Mixed
Northern Trust	75,696	0	For
Nationwide	74,467	0	For
T. Rowe Price	74,332	0	For
John Hancock	67,421	0	For
Legg Mason	66,563	0	For
Goldman Sachs	60,610	0	For
Pacific Life	57,810	0	For
Russell Investments	51,654	0	For
AIG/SunAmerica	45,437	0	For
Principal Exchange-Traded Funds	39,688	0	For
Bridge Builder Trust	35,340	0	For
PFM Multi-Manager Series Trust	34,403	0	For

Fund voting reports, all 44 managers: 29,404,563 for, 88,669 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 98 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
ARMISTICE CAPITAL, LLC	0	14,014,448	Against
Soleus Capital Management, L.P.	9,241,986	0	For
BlackRock	6,641,131	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,792,499	0	For
State Street	3,202,969	0	For
Nuveen	2,864,150	0	For
ACADIAN ASSET MANAGEMENT LLC	2,290,327	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	2,118,241	0	For
Ensign Peak Advisors, Inc	2,034,204	0	For
Voya	1,804,919	0	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	1,600,000	0	For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	1,359,200	0	For
Northern Trust	1,276,346	160	For
Renaissance	1,093,800	0	For
Stonepine Capital Management, LLC	1,040,241	0	For
Charles Schwab	743,615	0	For
MELLON INVESTMENTS Corp	738,305	0	For
Two Sigma	724,975	0	For
Wellington	673,325	0	For
UBS	672,750	45	For
BRIDGEWAY CAPITAL MANAGEMENT, LLC	547,400	0	For
SEI	477,940	0	For
MARSHALL WACE, LLP	0	438,562	Against
Connor, Clark & Lunn Investment Management Ltd.	415,464	0	For
AllianceBernstein	314,730	0	For

Institutional-manager reports, all 98 managers: 48,740,842 for, 14,796,569 against. Showing the 25 largest; see all in the interactive database.

7. TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR…

No official matchAUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR

Details: description as filed, votes by 44 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.

FOR: 29,404,563ABSTAIN: 88,669

Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPA” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	9,061,718	0	For
BlackRock	6,943,627	0	For
Fidelity	3,795,417	0	For
TIAA	2,854,841	0	For
Delaware/Macquarie	1,600,000	0	For
Voya	1,305,129	0	For
Charles Schwab	743,615	0	For
Equitable	609,860	0	For
BRIDGEWAY FUNDS INC	521,200	0	For
SEI	475,477	0	For
QUANTITATIVE MASTER SERIES LLC	305,297	0	For
Lincoln Financial	147,363	0	For
Brighthouse	56,766	88,669	Mixed
Northern Trust	75,696	0	For
Nationwide	74,467	0	For
T. Rowe Price	74,332	0	For
John Hancock	67,421	0	For
Legg Mason	66,563	0	For
Goldman Sachs	60,610	0	For
Pacific Life	57,810	0	For
Russell Investments	51,654	0	For
AIG/SunAmerica	45,437	0	For
Principal Exchange-Traded Funds	39,688	0	For
Bridge Builder Trust	35,340	0	For
PFM Multi-Manager Series Trust	34,403	0	For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

Largest RIGEL PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 175,406,146 shares outstanding at the time of that meeting.

Fund voting reports: top RIGEL PHARMACEUTICALS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	5.17%
2	BlackRock	3.96%
3	Fidelity	2.16%
4	TIAA	1.63%
5	Delaware/Macquarie	0.91%
6	Voya	0.74%
7	Charles Schwab	0.42%
8	Equitable	0.35%
9	BRIDGEWAY FUNDS INC	0.30%
10	SEI	0.27%

Institutional-manager reports: top RIGEL PHARMACEUTICALS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2023-2024
#	Asset manager	% of shares outstanding
1	ARMISTICE CAPITAL, LLC	7.99%
2	Soleus Capital Management, L.P.	5.27%
3	BlackRock	3.79%
4	GEODE CAPITAL MANAGEMENT, LLC	2.16%
5	State Street	1.83%
6	Nuveen	1.63%
7	ACADIAN ASSET MANAGEMENT LLC	1.31%
8	JACOBS LEVY EQUITY MANAGEMENT, INC	1.21%
9	Ensign Peak Advisors, Inc	1.16%
10	Voya	1.03%

Reported RIGEL PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

RIGEL PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
The Vanguard Group	5.10%	13G
Geode Capital	2.16%	13F
State Street	2.13%	13F
Nuveen	1.84%	13F
Renaissance Technologies	1.15%	13F
Millennium Management	1.07%	13F
Northern Trust	0.83%	13F
Wellington Management	0.48%	13F
Charles Schwab	0.42%	13F
BNY Mellon	0.30%	13F

Percentages above are of 175,406,146 shares outstanding, as reported by RIGEL PHARMACEUTICALS INC. on its Form 10-Q dated May 2, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RIGEL PHARMACEUTICALS INC.’s 10-Q dated May 2, 2024. This page is a static snapshot rebuilt weekly on November 1, 2026; a live search always shows the current data.

At RIGEL PHARMACEUTICALS INC.'s shareholder meeting held May 24, 2024, in the 2023-2024 proxy season, 127 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,012 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — RIGEL PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 74% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: RIGEL PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 29, 2024.

RIGEL PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.